The U.S. National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) Tech program has awarded Co-Dx™ $1.2 million to complete the development of its upper respiratory panel.
The multiplex test for influenza A/B, COVID-19, and respiratory syncytial virus runs on the firm’s Co-Dx PCR Home™ Testing Platform. Co-Dx will use the RADx funding to finish the assay’s development and prepare for clinical trials.
Read the article here: